Replacement mitral valve

Information

  • Patent Grant
  • 11045313
  • Patent Number
    11,045,313
  • Date Filed
    Monday, January 14, 2019
    5 years ago
  • Date Issued
    Tuesday, June 29, 2021
    2 years ago
Abstract
A prosthesis for placement within a native mitral valve includes an expandable frame having locking tabs disposed along a proximal end. A plurality of distal anchors are disposed along a distal end of the frame. Each distal anchor is provided with a cushion cover. An outer fabric member surrounds the frame and may extend outwardly from the frame in an expanded condition for providing an improved seal in the region of a mitral annulus. A valve body is positioned within an interior of the expandable from for allowing blood flow in only one direction. In preferred embodiments, the cushions are positioned over enlarged head portions of the distal anchors for further reducing trauma on surrounding tissue.
Description
BACKGROUND
Field

Certain embodiments disclosed herein relate generally to prostheses for implantation within a lumen or body cavity. In particular, certain embodiments relate to expandable prostheses such as replacement heart valves, such as for the mitral valve, that are configured to atraumatically grasp intralumenal tissue.


Background

Human heart valves, which include the aortic, pulmonary, mitral and tricuspid valves, function essentially as one-way valves operating in synchronization with the pumping heart. The valves allow blood to flow downstream, but block blood from flowing upstream. Diseased heart valves exhibit impairments such as narrowing of the valve or regurgitation, which inhibit the valves' ability to control blood flow. Such impairments reduce the heart's blood-pumping efficiency and can be a debilitating and life threatening condition. For example, valve insufficiency can lead to conditions such as heart hypertrophy and dilation of the ventricle. Thus, extensive efforts have been made to develop methods and apparatuses to repair or replace impaired heart valves.


Prostheses exist to correct problems associated with impaired heart valves. For example, mechanical and tissue-based heart valve prostheses can be used to replace impaired native heart valves. More recently, substantial effort has been dedicated to developing replacement heart valves, particularly tissue-based replacement heart valves that can be delivered with less trauma to the patient than through open heart surgery. Replacement valves are being designed to be delivered through minimally invasive procedures and even percutaneous procedures. Such replacement valves often include a tissue-based valve body that is connected to an expandable frame that is then delivered to the native valve's annulus.


These replacement valves are often intended to at least partially block blood flow. However, a problem occurs when blood flows around the valve on the outside of the prosthesis. For example, in the context of replacement heart valves, paravalvular leakage has proven particularly challenging. An additional challenge relates to the ability of such prostheses to be secured relative to intralumenal tissue, e.g., tissue within any body lumen or cavity, in an atraumatic manner. Further challenges arise when trying to controllably deliver and secure such prostheses in a location such as at a native mitral valve.


SUMMARY OF THE INVENTION

Embodiments of the present disclosure are directed to a prosthesis, such as but not limited to a replacement heart valve. According to some embodiments, a prosthesis can be configured to be deployed within a body cavity and prevent axial flow of fluid around an exterior of the prosthesis. The prosthesis can include an expandable frame configured to radially expand and contract for deployment within the body cavity, and an annular flap positioned around an exterior of the expandable frame. Further embodiments are directed to methods of delivering a prosthesis, e.g. a replacement heart valve, and methods of using a prosthesis to create a barrier to fluid flow exterior to the prosthesis (e.g., to prevent paravalvular leakage).


In some embodiments, the prosthesis can include an expandable frame having a proximal end and a distal end and a longitudinal axis extending therethrough. In some embodiments, the frame can be designed to radially expand and contract for deployment within the body cavity. The prosthesis can include an annular flap positioned around and secured to an exterior of the frame. The annular flap may have a distal edge secured at or near the distal end of the frame and extending to a proximal edge secured at an intermediate location on the frame between the proximal and distal ends. The prosthesis can include a valve body positioned within an interior of the expandable frame. In some embodiments, the valve body can include an inner skirt secured to the interior of the expandable frame and a plurality of leaflets designed to allow flow in a first direction and prevent flow in a second opposite direction. In some embodiments, an opening is defined at or near the distal end of the frame between the annular flap and the valve body which can provide access for fluid to flow into a space between the annular flap and the valve body. In some embodiments, the fluid flow into the space can cause the annular flap to move from a first configuration wherein the flap is closer to the frame to a second configuration wherein the flap is spaced further away from the frame to increase the surface area of the prosthesis and create a barrier to fluid flow exterior to the frame when deployed within the body cavity.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a proximal oriented, perspective view of an embodiment of a prosthesis illustrating a frame, a plurality of anchors, a band, a flap, and a valve body.



FIG. 1B is a distal oriented, perspective view of the prosthesis of FIG. 1A.



FIG. 2 is a front elevation view of the prosthesis of FIG. 1.



FIG. 3 is a front elevation view of another embodiment of a prosthesis.



FIG. 4 is a front elevation view of an embodiment of a frame.



FIG. 5 is a perspective view of an embodiment of an annular flap.



FIG. 6 is a front elevation view of the annular flap of FIG. 5.



FIG. 7 is a perspective view of an embodiment of a valve body.



FIG. 8 is a front perspective view of the valve body of FIG. 7.



FIG. 9 is a front elevation of an embodiment of a prosthesis illustrating a frame, a plurality of anchors, a band, a flap, and a valve body.



FIG. 10 is a front elevation another embodiment of a prosthesis.



FIG. 11A is a partial cross-sectional view of the prosthesis of FIG. 1 with the annular flap in a first configuration.



FIG. 11B is a partial cross-sectional view of the prosthesis of FIG. 11A with the annular flap in a first configuration.



FIG. 12A is a partial cross-sectional view of the prosthesis of FIG. 1 with the annular flap in a first configuration, the valve body being removed.



FIG. 12B is a partial cross-sectional view of the prosthesis of FIG. 12A with the annular flap in a first configuration.



FIGS. 13A-15 illustrate schematic representations of the prosthesis of FIG. 3 positioned within a heart, with FIGS. 13A-13C illustrating the prosthesis in situ with distal anchors contacting the ventricular side of a mitral valve annulus, FIGS. 14A-14B illustrating the prosthesis in situ with distal anchors not contacting the ventricular side of the mitral valve annulus, and FIG. 15 illustrating the prosthesis in situ with distal anchors not extending between the chordae tendineae.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The embodiment of FIGS. 1A-4 illustrates a prosthesis 10. The prosthesis 10 can have components, features, and/or functionality similar to those described in any of U.S. Publication Nos. 2014/0277390, 2014/0277422, and 2014/0277427, the entire contents of all which are incorporated by reference herein. With reference first to the embodiments of FIGS. 1A-4, the prosthesis 10 can include a frame 20, anchors 30, 34, a band 40, an annular flap or sail 50 and a valve body 60. The prosthesis 10 can include a proximal end 12 and a distal end 14 with openings defined at both ends 12, 14 such that fluid can flow therethrough. In some embodiments, the proximal end 12 can be placed in the left atrium while the distal end 14 can be placed in the left ventricle such that prosthesis 10 can function as a replacement for a mitral valve. As will be discussed in greater detail below and as discussed in U.S. Publication Nos. 2014/0277390, 2014/0277422, and 2014/0277427, the prosthesis 10 can allow blood flow in a first direction from the proximal end 12 to the distal end 14 while preventing blood flow in a second direction from the distal end 14 to the proximal end 12. For example, during diastole the valve body 60 may be open to allow blood flow from the proximal end 12 to the distal end 14, and during systole the valve body 60 may be closed to prevent blood flow from the distal end 14 to the proximal end 12.


With reference now to the embodiment of FIG. 4, the embodiment illustrates an expandable frame 20 of the prosthesis 10 which can have a proximal end 22 and a distal end 24. In some embodiments, such as the illustrated embodiment, the frame 20 can include an intermediate portion 26 which has a greater diameter than the diameter of the frame 20 at the proximal and/or distal ends 22, 24 when the frame 20 is in an expanded configuration. In some embodiments, such as the illustrated embodiment, the frame 20 can include an intermediate portion 26 which has a greater cross-sectional area than the cross-sectional area of the frame 20 at the proximal and/or distal ends 22, 24 when the frame 20 is in an expanded configuration. The frame 20 can be designed to expand radially and contract for deployment within a body cavity, such as at a heart valve location such as the mitral valve. For example, as described in greater detail in U.S. Publication Nos. 2014/0277390, 2014/0277422, and 2014/0277427, the frame 20 can include a plurality of struts which define a plurality of foreshortening cells. In some embodiments, the frame 20 can be designed to radially and contract radially from a longitudinal axis 28 extending through the frame 20. As illustrated in the embodiments of FIGS. 1-4, the proximal end 22 can define a proximal opening 23 and the distal end 24 can define a distal opening 25.


With continued reference to the embodiments of FIGS. 1A-4 which illustrates the prosthesis 10, in some embodiments the prosthesis 10 can include one or more distal anchors 30. The distal anchors 30 can be positioned along or proximate a distal end 24 of the frame 20 and can be connected to the frame 20. The distal anchors 30 can be designed such that when the frame 20 is in an expanded configuration an end or tip 32 of each distal anchor 30 is positioned radially outward from the frame 20 and extends generally in a proximal direction. In some embodiments, the prosthesis 10 can include one or more proximal anchors 34. The proximal anchors 34 can be positioned along or proximate a proximal end 22 of the frame 20 and can be connected to the frame 20. The proximal anchors 34 can be designed such that when the frame 20 is in an expanded configuration an end or tip 36 of each proximal anchor 34 is positioned radially outward from the frame 20 and extends generally in a distal direction. In some embodiments, one or more anchors 30, 34 can include cushions 38, 39 covering one or more of such anchors.


In some embodiments, the cushion 38 can be formed from two separate pieces of material such as an inner portion positioned within a covering such that the covering forms a layer surrounding the inner portion. For example, the inner portion can be wholly contained within the covering. In some embodiments, the inner portion can be formed of a foam material such that the inner portion is at least somewhat compliant and the covering can be formed of a biocompatible, fabric material. The embodiment of FIGS. 1A, 1B and 2 illustrates cushions 38 on alternating distal anchors 30, the cushions 38 extending partially from an end or tip of the anchor 30 towards the connection between the anchor 30 and the frame 20. Use of cushions 38 on alternating distal anchors 30 can maintain a smaller form factor while in the prosthesis 10 is in a contracted state for delivery. As such, for embodiments having twelve distal anchors 30, a total of six distal anchors 30 can have cushions 38 and a total of six distal anchors 30 may not have a cushion 38. The cushions 38 can advantageously increase contact area of the anchors 30 on tissue. This can reduce trauma between the anchor 30 and such tissue. Moreover, this can facilitate growth of tissue in and/or around the anchor 30 in embodiments where the cushions 38 are formed of a material which encourages tissue growth. The cushions 38 on anchors 30 adjacent anchors 30 without a cushion 38 can also beneficially reduce any potential trauma caused by adjacent anchors 30 without a cushion 38.


The embodiment of FIG. 3 illustrates cushions 38, 39 on all distal anchors 30. As shown some of the distal anchors 30 include thicker cushions 38 than other distal anchors 30. The cushions 38, 39 can extend the majority or entirety of the length of the anchor 30 from an end or tip of the anchor 30 towards the connection between the anchor 30 and the frame 20. As shown, two distal anchors 30 include thicker cushions 38 with a distal anchor 30 having a thinner cushion 39 positioned therebetween. As such, for embodiments having twelve distal anchors 30, a total of eight distal anchors 30 can have thicker cushions 38 and a total of four distal anchors 30 can include thinner cushions 39. The thicker cushions 38 can be formed of an inner portion and a cover layer, with the inner portion being formed from a compliant material, such as foam, and the covering can be formed of a biocompatible, fabric material. As shown, the inner portion can be positioned only around a portion of the anchor 30 whereas the covering can extend the majority or entirety of the length of the anchor 30. The thinner cushion 39 can be a cover layer with a thinner inner portion or without an inner portion. The inner portion and/or the covering can be formed of a material which encourages tissue growth.


Other configurations of cushions 38, 39 can also be used. For example, in some embodiments, the cushions 38, 39 can be included on proximal anchors 34. In some embodiments, the cushions 38, 39 can be positioned on other portions of the frame 20 such as, but not limited to, one or more of the struts forming the frame 20. The cushions 38, 39 can advantageously increase contact area of the prosthesis 10 on tissue. This can reduce trauma between the frame 20 and such tissue. Moreover, this can facilitate growth of tissue in and/or around the frame 20 in embodiments where the cushions 38, 39 are formed of a material which encourages tissue growth. In some embodiments, the covering of cushions 38, 39 can extend from the annular flap 50 and be formed from materials similar to those of the annular flap 50. The covering of cushions 38, 39 can cover a majority or the entirety of the distal anchors 30 as shown in FIG. 3. In some embodiments, the cushions 38, 39 can be attached to the distal anchors 30 via circumferential stitching about a longitudinal axis of the distal anchor 30.


With reference to the embodiments of FIGS. 1A-3, in some embodiments the prosthesis 10 can include a band 40 along or proximate the proximal end 22 of the frame 20. The band 40 can include features and perform functions similar to those described in U.S. patent application Ser. No. 13/403,929 filed Feb. 23, 2012, titled REPLACEMENT VALVE AND METHOD, published as U.S. Publication No. 2012/0215303, the entire contents of which is incorporated by reference herein.


With reference to the embodiments of FIGS. 1A-3, 5 and 6, the prosthesis 10 can include an annular flap 50 which can be positioned around and secured to an exterior of the frame 20. The annular flap 50 can have a distal edge 52 secured at or proximate the distal end 24 of the frame 20 and extend to a proximal edge 54 secured at or proximate an intermediate location, such as the intermediate portion 26, on the frame 20 between the proximal and distal ends 22, 24. In some embodiments, the distal edge 52 of the annular flap 50 can be provided with a shape that generally corresponds to the shape of the frame 20. This can facilitate the securement of the flap 50 to the frame 20. For example, as illustrated in the embodiments of FIGS. 1A-3, 5 and 6, the distal edge 52 can include a generally triangular pattern 56 which follows the generally triangular, zig-zag or undulating pattern of the struts of frame 20 along the distal end 24 of frame 20. Other shapes and/or patterns 56 can be used along the distal edge 52 of the annular flap 50. In some embodiments, the distal edge 52 of the annular flap 50 can have no pattern. In some embodiments the distal edge 52 does not follow the pattern of the struts of the frame 20 and/or can have a different pattern from that of the struts.


In some embodiments, such as the embodiments of FIGS. 1A-3, 5 and 6, the annular flap 50 can have a flange 58. The flange 58 can extend generally radially outward in a direction generally orthogonal to the longitudinal axis 28 extending through the frame 20. In some embodiments, the flange 58 can also project proximally and/or distally. The flange 58 can be used to further prevent or inhibit backflow of fluids around the prosthesis 10. In some embodiments, the flange 58 can be formed from a first layer of resilient material, such as polyethylene terephthalate (PET) or any other biocompatible material, which extends radially outward from the frame 10. In some embodiments, a second layer of resilient material, such as PET or any other biocompatible material, can extend from the first layer in a distal direction towards a distal end 24 of the frame 20. In some embodiments, the first and second layers can be connected together using a suitable mechanism such as adhesives or sutures. In some embodiments, the annular flap 50 can be formed from a single layer of resilient material. In some embodiments, the first and/or second layers can be formed from a deformable material. In some embodiments, the first and/or second layers can be formed from a material which is wholly or substantially fluid impermeable. The annular flap 50 can also include other structures, such as wires formed from resilient materials such as nitinol, to allow at least portions of the annular flap 50 to retain a particular shape. These structures may be positioned on an inner surface of the annular flap 50.


In some embodiments, the flange 58 can be formed when the annular flap 50 is in an expanded configuration. When the flap is in an expanded configuration, such as illustrated in the embodiment of FIG. 6, the radius of the annular flap 50 can decrease distal of the flange 58. As will be described in further detail below, the annular flap 50 can have a first, collapsed or deflated configuration in which the flap 50 is closer to the frame 20 to a second, expanded or inflated configuration in which the flap 50 is spaced further away from the frame 20. The expanded configuration can increase the surface area of the prosthesis 10 and create a barrier to fluid flow exterior to the frame 20 when deployed within a body cavity. The transition from the first configuration to the second configuration, and from the second configuration to the first configuration, can be triggered by blood flow into and out of the interior region of the flap 50, as described further below.


With reference to the embodiments of FIGS. 1A-3 and 7-10, the prosthesis 10 can include a valve body 60 positioned within an interior of the frame 20. In some embodiments, the valve body 60 can include an inner skirt 62 secured to the interior of the frame 20. The valve body 60 can include a plurality of leaflets 64 which can be designed to allow flow in a first direction, such as a proximal to distal direction, while preventing flow in a second direction, such as a distal to proximal direction. In some embodiments, the leaflets 64 have a curved, proximal edge which is fixed to the inner skirt 62 and a distal edge which freely moves. In such embodiments, movement of the distal edges towards and away from each other can allow the valve body 60 to open and close depending on the direction of flow. Accordingly, the valve body 60 can function as a one-way valve such as a mitral valve. In some embodiments, the leaflets 64 are secured to the inner skirt 62. The leaflets 64 and the inner skirt 62 can be manufactured from the same material or from different materials. For example, the inner skirt 62 can be manufactured from a more rigid material than the leaflets 64. In some embodiments, the distal end 66 of the inner skirt 62 can be secured at or proximate the distal end 24 of the frame 20. In some embodiments, such as is illustrated in the embodiments of FIGS. 9 and 10, the distal end 66 of the inner skirt 62 can be positioned slightly proximal of the distal end 24 of the frame 20. This can allow facilitate blood flow around the outside of the inner skirt 62 and into the annular flap 50. The inner skirt 62 can include one or more openings or cutouts 67 positioned along a distal end 66 of the inner skirt 62. This can further facilitate blood flow around the outside of the inner skirt 62. In some embodiments, the valve body 60 can include arms 68 to further secure the valve body 60 to the frame 20.


Reference is now made to the embodiments of FIGS. 11A-B and 12A-B which illustrate two configurations of the annular flap. It should be noted that the embodiment of FIGS. 12A-B is similar to the embodiment of FIG. 11A-B with the valve body 60 removed. As shown in the embodiments of FIGS. 11A and 12A, in a first configuration the annular flap 50 is positioned closer to the frame 20. In the event that fluid flows in a second direction, such as a distal to proximal direction, at least a portion of the fluid can enter into an opening between the frame 20 and the annular flap 50, such as opening or cutout 67 formed along the distal end 66 of the inner skirt 62, and collect within a space 59 such that the annular flap 50 takes on the second configuration as shown in the embodiments of FIGS. 11B and 12B. As shown in the embodiments of FIG. 1B, the frame 20 can be positioned within the space 59 between the annular flap 50 and the valve body 60. This effect can be enhanced if the valve body 60 is designed to prevent fluid flow in the second direction (e.g., distal to proximal), such that a substantial portion of fluid is forced around and into the annular flap 50. The annular flap 50 can revert back to the first configuration when fluid flows in a first direction, such as a proximal to distal direction, such that fluid is expelled from within the space 59. In some embodiments, the space 59 can be formed between the inner skirt 62 and the flap 50. For example, both the inner skirt 62 and the flap 50 can be connected to the frame 20 along this region, such as along a proximal edge 54 of the flap 50, such that the inner skirt 62 and flap 50 serve as a barrier to flow of fluid outward from space 59.


Reference is now made to FIGS. 13A-15 which illustrate schematic representations of an embodiment of a replacement heart valve 10 positioned within a native mitral valve of a heart 100. A portion of the native mitral valve is shown schematically and represents typical anatomy, including a left atrium 102 positioned above an annulus 106 and a left ventricle 104 positioned below the annulus 106. The left atrium 102 and left ventricle 104 communicate with one another through a mitral annulus 106. Also shown schematically in FIGS. 13A-15 is a native mitral leaflet 108 having chordae tendineae 110 that connect a downstream end of the mitral leaflet 108 to the papillary muscle of the left ventricle 104. The portion of the replacement heart valve 10 disposed upstream of the annulus 106 (toward the left atrium) can be referred to as being positioned supra-annularly. The portion generally within the annulus 106 is referred to as positioned intra-annularly. The portion downstream of the annulus 106 is referred to as being positioned sub-annularly (toward the left ventricle). In the illustrated embodiment, only a part of the foreshortening portion is positioned intra-annularly or sub-annularly, and the rest of the replacement heart valve 10 is supra-annular.


As shown in the situations illustrated in FIGS. 13A-14, the replacement heart valve 10 can be disposed so that the mitral annulus 106 is between the distal anchors 30 and the proximal anchors 34. In some situations, the prosthesis 10 can be positioned such that ends or tips 32 of the distal anchors 30 contact the annulus 106 as shown, for example, in FIGS. 13A-13C. In some situations, the prosthesis 10 can be positioned such that ends or tips 32 of the distal anchors 30 do not contact the annulus 106 as shown, for example, in FIGS. 14A-14B. In some situations, the prosthesis 10 can be positioned such that the distal anchors 30 do not extend around the leaflet 108 as shown in FIG. 15. While FIGS. 13A-15 are described separately below, it should be understood that one or more of the situations illustrated in FIGS. 13A-15 may be present when the prosthesis 10 is positioned at the implantation location, such as a native mitral valve. For example, in some situations the prosthesis 10 may be positioned such that some distal anchors 30 may contact the annulus 106 while other distal anchors 30 may not.


With reference first to the situations illustrated in FIGS. 13A-14B, the replacement heart valve 10 can be positioned so that the ends or tips 32 of the distal anchors 30 are on a ventricular side of the mitral annulus 106 and the ends or tips of 36 the proximal anchors 34 are on an atrial side of the mitral annulus 106. The distal anchors 30 can be positioned such that the ends or tips 32 of the distal anchors 30 are on a ventricular side of the native leaflets beyond a location where chordae tendineae 110 connect to free ends of the native leaflets. The distal anchors 30 may extend between at least some of the chordae tendineae 110 and, in some situations such as those shown in FIGS. 13A-13C, can contact or engage a ventricular side of the annulus 106. It is also contemplated that in some situations, such as those shown in FIGS. 14A and 14B, the distal anchors 30 may not contact the annulus 106, though the distal anchors 30 may still contact the native leaflet 108. In some situations, the distal anchors 30 can contact tissue of the left ventricle 104 beyond the annulus 106 and/or a ventricular side of the leaflets.


During delivery, the distal anchors 30 (along with the frame 20) can be moved toward the ventricular side of the annulus 106 with the distal anchors 30 extending between at least some of the chordae tendineae 110 to provide tension on the chordae tendineae 110. The degree of tension provided on the chordae tendineae 110 can differ. For example, little to no tension may be present in the chordae tendineae 110 as shown in FIG. 13C where the leaflet 108 is shorter than or similar in size to the distal anchors 30. A greater degree of tension may be present in the chordae tendineae 110 as shown in FIGS. 13A and 13B where the leaflet 108 is longer than the distal anchors 30 and, as such, takes on a compacted form and is pulled proximally. An even greater degree of tension may be present in the chordae tendineae 110 as shown in FIGS. 14A and 14B where the leaflets 108 are even longer relative to the distal anchors 30. As shown in FIGS. 14A and 14B, the leaflet 108 is sufficiently long such that the distal anchors 30 do not contact the annulus 106.


The proximal anchors 34 can be positioned such that the ends or tips 36 of the proximal anchors 34 are adjacent the atrial side of the annulus 106 and/or tissue of the left atrium 102 beyond the annulus 106. In some situations, some or all of the proximal anchors 34 may only occasionally contact or engage atrial side of the annulus 106 and/or tissue of the left atrium 102 beyond the annulus 106. For example, as shown in FIGS. 13A and 13B, the proximal anchors 34 may be spaced from the atrial side of the annulus 106 and/or tissue of the left atrium 102 beyond the annulus 106. The proximal anchors 34 could provide axial stability for the prosthesis 10. In some situations such as those shown in FIGS. 13A and 14A, some or all of the proximal anchors 34 may not contact the annular flap 50. This may occur when the annular flap 50 is in a collapsed configuration although it may also occur when the annular flap 50 is in an expanded configuration. In some situations such as those shown in FIGS. 13B, 13C and 14B, some or all of the proximal anchors 34 may contact the annular flap 50. This may occur when the annular flap 50 is in an expanded configuration although it may also occur when the annular flap 50 is in a collapsed configuration. It is also contemplated that some or all of the proximal anchors 34 may contact the atrial side of the annulus 106 and/or tissue of the left atrium 102 beyond the annulus 106


With continued reference to the situations illustrated in FIGS. 13A-14B, the annular flap 50 can be positioned such that a proximal portion 51 of the annular flap 50 is positioned along or adjacent an atrial side of the annulus 106. The proximal portion 51 can be positioned between the atrial side of the annulus 106 and the proximal anchors 34. The proximal portion 51 can extend radially outward such that the annular flap 50 is positioned along or adjacent tissue of the left atrium 102 beyond the annulus 106. The annular flap 50 can create a seal over the atrial side of the annulus 106 when the flap 50 is in the expanded state.


The flap 50 can transition from the collapsed state to the expanded state during systole when pressure in the left ventricle 104 increases. This increased pressure within the left ventricle 104 can cause blood within the left ventricle 104 to be directed to areas of lower pressure, such as the aorta (not shown) and the left atrium 102. As noted above, during systole the valve body 60 may be closed to prevent blood from flowing back into the left atrium 102. A substantial portion of blood can forced around the frame 20 and valve body 60 and into the annular flap 50 such that the flap 50 can expand. Sealing along an atrial side of the annulus 106 can be particularly effective. The left atrium 102 can be at a lower pressure in comparison to the pressure of the space 59 between the annular flap 50 and the valve body 50, which is closer to the pressure of the left ventricle 104. The existence of such a pressure differential between the left atrium 102 and the space 59 during systole can allow the flap 50 to apply a greater force to surrounding tissue within the left atrium 102. During diastole, where blood flows from the left atrium 102 towards the left ventricle 104, the flap 50 can transition from the expanded state back to the collapsed state.


In some situations such as those shown in FIGS. 13A and 14A, the annular flap 50 may not contact the wall of the heart 100. This may occur when the annular flap 50 is in a collapsed configuration although it may also occur when the annular flap 50 is in an expanded configuration. In some situations such as those shown in FIGS. 13B, 13C and 14B, the annular flap 50 may contact the wall of the heart 100. This may occur when the annular flap 50 is in an expanded configuration although it may also occur when the annular flap 50 is in a collapsed configuration. As shown in FIGS. 13A-14B, the annular flap 50 can also assist in filling gaps which exist between the leaflet 108 and the frame 20 (portions of which are illustrated in dashed lines).


In some situations such as that shown in FIG. 15, the leaflet 108 may not be captured between the frame 20 (portions of which are shown in dashed lines) and the distal anchors 30. As shown, the anchor 30 may be positioned along an atrial surface of the leaflet 108. The anchor 30 may also be positioned along an inner surface of the annulus 106. It is also contemplated that the anchor 30 may exert a force against the leaflet 108 such that the leaflet 108 is pushed radially outward, relative to the longitudinal axis 28, towards a wall of the heart 100. In such situations, the flap 50 can create a seal intra-annularly and/or along an atrial side of the leaflet 108. In alternative situations (not shown), the flap 50 can create a seal along a ventricular side of the annulus 106. For example, the replacement heart valve 10 may be disposed in the mitral annulus such that a portion of the annular flap 50 is positioned on the ventricular side of the native annulus 106.


As noted above, although the in vivo situations of FIG. 13A-15 have been described separately, it should be understood that one or more of these situations may be present when a prosthesis is positioned at the implantation location, such as a native mitral valve. For example, one or more of the distal anchors 30 may not capture the leaflet 108 whereas the remaining anchors 30 may capture the leaflet 108. As another example, when the prosthesis 10 is positioned within the native mitral valve, the annular flap 50 can contact the wall of the heart 100 along one or more portions of an outermost circumference of the proximal portion 51 and may not contact the wall of the heart 100 along other portions of the outermost circumference of the proximal portion 51. For example, the annular flap 50 may contact the wall of the heart 100 along an approximately 180 degree portion of the outermost circumference of the proximal portion 51 and may not contact the wall of the heart 100 along the remaining, approximately 180 degree portion of the outermost circumference of the proximal portion 51.


Replacement heart valves can be delivered to a patient's heart mitral valve annulus in various ways, such as by open surgery, minimally-invasive surgery, and percutaneous or transcatheter delivery through the patient's vasculature. In some embodiments, the replacement heart valve can be delivered transapically or transfemorally.


Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.


Similarly, this method of disclosure is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.

Claims
  • 1. A prosthesis for placement within a native heart valve having a native heart valve annulus, the prosthesis comprising: an expandable frame comprising a proximal end, a distal end, and a middle region between the proximal and distal ends, the expandable frame configured to radially expand and contract for deployment within the native heart valve, the proximal end comprising a plurality of locking tabs configured to secure the prosthesis to a delivery catheter;a plurality of distal anchors connected to the expandable frame and extending from the distal end of the expandable frame, at least a portion of each of the plurality of distal anchors extending generally proximally when the expandable frame is in an expanded configuration, each of the plurality of distal anchors comprising a cushion on an end of the distal anchor;an outer fabric member surrounding the expandable frame, the outer fabric member having a distal end portion and extending proximally from the distal end portion of the outer fabric member to a middle portion having a larger diameter than the distal end portion of the outer fabric member and then to a proximal end portion of the outer fabric member having a smaller diameter than the middle portion, wherein the middle portion is positioned radially outward of the middle region of the expandable frame and proximal to the ends of the distal anchors so as to define an annular space between the outer fabric member and the expandable frame, wherein the middle portion is configured to engage the native heart valve annulus when the expandable frame is in an expanded configuration within the native heart valve, and wherein, when the prosthesis is in operation after placement within the native heart valve, the outer fabric member is configured to create a barrier to fluid flow exterior to the expandable frame when the expandable frame is in the expanded configuration within the native heart valve; anda valve body positioned within an interior of the expandable frame, wherein the valve body comprises a plurality of leaflets configured to allow flow in a first direction and prevent flow in a second opposite direction.
  • 2. The prosthesis of claim 1, wherein the middle region has a larger cross-sectional dimension than the proximal and distal ends when the expandable frame is in an expanded configuration.
  • 3. The prosthesis of claim 1, wherein the cushions are made from a fabric material and are adapted for reducing trauma to surrounding tissue.
  • 4. The prosthesis of claim 1, wherein the valve body comprises: an inner skirt comprising a proximal end, the proximal end comprising edges that undulate between upper portions and lower portions; andone or more arms, each arm attached to the inner skirt between the upper portions, the one or more arms extending along and secured to a strut of the expandable frame.
  • 5. The prosthesis of claim 4, wherein the plurality of leaflets are attached to the inner skirt, wherein the inner skirt and the plurality of leaflets are manufactured from different materials, and wherein the inner skirt is manufactured from a more rigid material than the plurality of leaflets.
  • 6. The prosthesis of claim 1, wherein the expandable frame is metal.
  • 7. The prosthesis of claim 1, wherein the plurality of distal anchors comprises a first set of distal anchors and a second set of distal anchors, each distal anchor of the first set comprising a first individual cushion and each distal anchor of the second set comprising a second individual cushion smaller than the first individual cushion.
  • 8. The prosthesis of claim 7, wherein, in the expanded configuration, each distal anchor of the first set extends further proximally than each distal anchor of the second set.
  • 9. The prosthesis of claim 1, wherein the ends of the distal anchors have enlarged head portions.
  • 10. The prosthesis of claim 9, wherein the enlarged head portions comprise central openings.
  • 11. The prosthesis of claim 10, wherein the cushions are disposed over the enlarged head portions.
  • 12. The prosthesis of claim 11, wherein the cushions are made of fabric.
  • 13. The prosthesis of claim 1, wherein the plurality of distal anchors are uncovered between the cushion and the outer fabric member.
  • 14. The prosthesis of claim 1, further comprising wire structures formed from resilient material that are positioned on an inner surface of the outer fabric member to allow at least portions of the outer fabric member to retain a particular shape.
  • 15. The prosthesis of claim 1, wherein a diameter of the outer fabric member increases from a proximal-most edge of the proximal end portion of the outer fabric member toward the middle portion of the outer fabric member and then decreases from the middle portion to a distal edge of the distal end portion.
  • 16. A prosthesis for placement within a native mitral valve having a native mitral valve annulus, the prosthesis comprising: an expandable frame comprising a proximal end, a distal end, and a middle region between the proximal and distal ends, the expandable frame configured to radially expand and contract for deployment within the native mitral valve, the proximal end comprising a plurality of locking tabs configured to secure the prosthesis to a delivery catheter;a plurality of distal anchors connected to the expandable frame and extending from the distal end of the expandable frame, at least a portion of each of the plurality of distal anchors extending generally proximally when the expandable frame is in an expanded configuration, each of the plurality of distal anchors comprising a cushion on an end of the distal anchor, and each of the plurality of distal anchors having enlarged head portions having a central opening;an outer fabric member surrounding the frame, the outer fabric member having a distal end portion positioned proximate to where the plurality of distal anchors connect to the expandable frame and extending proximally from the distal end portion of the outer fabric member to a middle portion having a larger diameter than the distal end portion of the outer fabric member, wherein the middle portion is positioned radially outward of the middle region of the expandable frame and proximal to the ends of the distal anchors, and wherein the middle portion is configured to engage the native mitral valve annulus when the expandable frame is in an expanded configuration within the native mitral valve;an inner skirt comprising a proximal end, the proximal end comprising edges that undulate between upper portions and lower portions;one or more arms, each arm attached to the inner skirt between the upper portions, the one or more arms extending along and secured to a strut of the expandable frame; anda valve body positioned within an interior of the expandable frame, wherein the valve body comprises a plurality of leaflets configured to allow flow in a first direction and prevent flow in a second opposite direction, wherein the valve body is attached to the inner skirt;wherein the middle region has a larger cross-sectional dimension than the proximal and distal ends when the expandable frame is in an expanded configuration; andwherein the plurality of distal anchors comprises a first set of distal anchors and a second set of distal anchors, each distal anchor of the first set comprising a first individual cushion and each distal anchor of the second set comprising a second individual cushion smaller than the first individual cushion.
  • 17. The prosthesis of claim 16, wherein, in the expanded configuration, each distal anchor of the first set extends further proximally than each distal anchor of the second set.
  • 18. A prosthesis for placement within a native heart valve having a native heart valve annulus, the prosthesis comprising: an expandable frame comprising a proximal end, a distal end, and a middle region between the proximal and distal ends, the expandable frame configured to radially expand and contract for deployment within the native heart valve;a plurality of distal anchors connected to the expandable frame and extending from the distal end of the expandable frame, at least a portion of each of the plurality of distal anchors extending generally proximally when the expandable frame is in an expanded configuration, each of the plurality of distal anchors comprising a cushion on an end of the distal anchor;an outer fabric member surrounding the expandable frame, the outer fabric member having a distal end portion positioned proximate to where the plurality of distal anchors connect to the expandable frame and extending proximally from the distal end portion of the outer fabric member to a middle portion of the outer fabric member having a larger diameter than the distal end portion of the outer fabric member, wherein the middle portion is positioned radially outward of the middle region of the expandable frame and proximal to the ends of the distal anchors, and wherein the middle portion is configured to engage the native heart valve annulus when the expandable frame is in an expanded configuration within the native heart valve; anda valve body positioned within an interior of the expandable frame, wherein the valve body comprises an inner skirt secured to the interior of the expandable frame and a plurality of leaflets configured to allow flow in a first direction and prevent flow in a second opposite direction,wherein the leaflets each comprise a proximal edge which is fixed to the inner skirt and a distal edge which freely moves,wherein there is clearance between the leaflets and the expandable frame,wherein the inner skirt and the leaflets are manufactured from different materials, andwherein the inner skirt is manufactured from a more rigid material than the plurality of leaflets.
  • 19. The prosthesis of claim 18, wherein the proximal edge is curved.
  • 20. The prosthesis of claim 18, wherein the middle region of the expandable frame has a larger cross-sectional dimension than the proximal and distal ends when the expandable frame is in the expanded configuration.
  • 21. The prosthesis of claim 18, wherein a distal end of the inner skirt is secured at or proximate the distal end of the expandable frame.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/462,438, filed Mar. 17, 2017, now U.S. Pat. No. 10,179,044, which is a continuation of U.S. application Ser. No. 14/716,507, filed May 19, 2015, which claims priority to U.S. Provisional Application No. 62/000,309 filed May 19, 2014, which is hereby incorporated herein by reference in its entirety and is to be considered a part of this specification.

US Referenced Citations (427)
Number Name Date Kind
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3739402 Cooley et al. Jun 1973 A
4056854 Boretos et al. Nov 1977 A
4079468 Liotta et al. Mar 1978 A
4204283 Bellhouse et al. May 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4339831 Johnson Jul 1982 A
4340977 Brownlee et al. Jul 1982 A
4470157 Love Sep 1984 A
4477930 Totten et al. Oct 1984 A
4490859 Black et al. Jan 1985 A
4553545 Maass et al. Nov 1985 A
4777951 Cribier et al. Oct 1988 A
4865600 Carpentier et al. Sep 1989 A
4994077 Dobben Feb 1991 A
5326371 Love et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5370685 Stevens Dec 1994 A
5411552 Andersen et al. May 1995 A
5415667 Frater May 1995 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5697382 Love et al. Dec 1997 A
5840081 Andersen et al. Nov 1998 A
5855601 Bessler et al. Jan 1999 A
5957949 Leonhardt et al. Sep 1999 A
6086612 Jansen Jul 2000 A
6113631 Jansen Sep 2000 A
6168614 Andersen et al. Jan 2001 B1
6251093 Valley et al. Jun 2001 B1
6312465 Griffin et al. Nov 2001 B1
6358277 Duran Mar 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6458153 Bailey et al. Oct 2002 B1
6482228 Norred Nov 2002 B1
6527800 McGuckin, Jr. et al. Mar 2003 B1
6582462 Andersen et al. Jun 2003 B1
6610088 Gabbay Aug 2003 B1
6629534 St. Goar et al. Oct 2003 B1
6652578 Bailey et al. Nov 2003 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6712836 Berg et al. Mar 2004 B1
6716207 Farnholtz Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6746422 Noriega et al. Jun 2004 B1
6749560 Konstorum et al. Jun 2004 B1
6767362 Schreck Jul 2004 B2
6780200 Jansen Aug 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6875231 Anduiza et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
7186265 Sharkawy et al. Mar 2007 B2
7192440 Andreas et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7276078 Spenser et al. Oct 2007 B2
7393360 Spenser et al. Jul 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7462191 Spenser et al. Dec 2008 B2
7510575 Spenser et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7553324 Andreas et al. Jun 2009 B2
7585321 Cribier Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7628805 Spenser et al. Dec 2009 B2
7753949 Lamphere et al. Jul 2010 B2
7803185 Gabbay Sep 2010 B2
7806919 Bloom et al. Oct 2010 B2
7815673 Bloom et al. Oct 2010 B2
7914569 Nguyen et al. Mar 2011 B2
7947075 Goetz et al. May 2011 B2
7972378 Tabor et al. Jul 2011 B2
7981151 Rowe Jul 2011 B2
7993392 Righini et al. Aug 2011 B2
8043360 McNamara Oct 2011 B2
8070800 Lock et al. Dec 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8075615 Eberhardt et al. Dec 2011 B2
8080054 Rowe Dec 2011 B2
8092520 Quadri Jan 2012 B2
8109996 Stacchino et al. Feb 2012 B2
8118866 Herrmann et al. Feb 2012 B2
8136218 Millwee et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8157852 Bloom et al. Apr 2012 B2
8167934 Styrc et al. May 2012 B2
8182530 Huber May 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8219229 Cao et al. Jul 2012 B2
8220121 Hendriksen et al. Jul 2012 B2
8221493 Boyle et al. Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8246675 Zegdi Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8313525 Tuval et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8353953 Giannetti et al. Jan 2013 B2
8414645 Dwork et al. Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8454685 Hariton et al. Jun 2013 B2
8460368 Taylor et al. Jun 2013 B2
8470023 Eidenschink et al. Jun 2013 B2
8475521 Suri et al. Jul 2013 B2
8475523 Duffy Jul 2013 B2
8479380 Malewicz et al. Jul 2013 B2
8486137 Suri et al. Jul 2013 B2
8491650 Wiemeyer et al. Jul 2013 B2
8500733 Watson Aug 2013 B2
8500798 Rowe et al. Aug 2013 B2
8511244 Holecek et al. Aug 2013 B2
8512401 Murray, III et al. Aug 2013 B2
8518096 Nelson Aug 2013 B2
8518106 Duffy et al. Aug 2013 B2
8562663 Mearns et al. Oct 2013 B2
8579963 Tabor Nov 2013 B2
8579964 Lane et al. Nov 2013 B2
8579965 Bonhoeffer et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8585756 Bonhoeffer et al. Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8597348 Rowe et al. Dec 2013 B2
8640521 Righini et al. Feb 2014 B2
8647381 Essinger et al. Feb 2014 B2
8652145 Maimon et al. Feb 2014 B2
8652201 Oberti et al. Feb 2014 B2
8652202 Alon et al. Feb 2014 B2
8673000 Tabor et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8679404 Liburd et al. Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8721714 Kelley May 2014 B2
8728154 Alkhatib May 2014 B2
8728155 Montorfano et al. May 2014 B2
8740974 Lambrecht et al. Jun 2014 B2
8740976 Tran et al. Jun 2014 B2
8747458 Tuval et al. Jun 2014 B2
8747459 Nguyen et al. Jun 2014 B2
8764818 Gregg Jul 2014 B2
8771344 Tran et al. Jul 2014 B2
8778020 Gregg et al. Jul 2014 B2
8784337 Voeller et al. Jul 2014 B2
8784478 Tuval et al. Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8790387 Nguyen et al. Jul 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8828079 Thielen et al. Sep 2014 B2
8845718 Tuval et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870950 Hacohen Oct 2014 B2
8876893 Dwork et al. Nov 2014 B2
8911455 Quadri et al. Dec 2014 B2
8926693 Duffy et al. Jan 2015 B2
8926694 Costello Jan 2015 B2
8939960 Rosenman et al. Jan 2015 B2
8945209 Bonyuet et al. Feb 2015 B2
8961593 Bonhoeffer et al. Feb 2015 B2
8961595 Alkhatib Feb 2015 B2
8974524 Yeung et al. Mar 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986372 Murry, III et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8998980 Shipley et al. Apr 2015 B2
9011523 Seguin Apr 2015 B2
9011524 Eberhardt Apr 2015 B2
9028545 Taylor May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9055937 Rowe et al. Jun 2015 B2
9066801 Kovalsky et al. Jun 2015 B2
9078751 Naor Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9125738 Figulla et al. Sep 2015 B2
9161834 Taylor et al. Oct 2015 B2
9173737 Hill et al. Nov 2015 B2
9180004 Alkhatib Nov 2015 B2
9186249 Rolando et al. Nov 2015 B2
9220594 Braido et al. Dec 2015 B2
9241790 Lane et al. Jan 2016 B2
9248014 Lane et al. Feb 2016 B2
9277990 Klima et al. Mar 2016 B2
9277993 Gamarra et al. Mar 2016 B2
9289291 Gorman, III et al. Mar 2016 B2
9289296 Braido et al. Mar 2016 B2
9295551 Straubinger et al. Mar 2016 B2
9326815 Watson May 2016 B2
9331328 Eberhardt et al. May 2016 B2
9339382 Tabor et al. May 2016 B2
9351831 Braido et al. May 2016 B2
9351832 Braido et al. May 2016 B2
9364321 Alkhatib et al. Jun 2016 B2
9445897 Bishop et al. Sep 2016 B2
9456877 Weitzner et al. Oct 2016 B2
9681968 Goetz et al. Jun 2017 B2
9700329 Metzger et al. Jul 2017 B2
9700411 Klima et al. Jul 2017 B2
9795479 Lim et al. Oct 2017 B2
9833313 Board et al. Dec 2017 B2
9861473 Lafontaine Jan 2018 B2
9861476 Salahieh et al. Jan 2018 B2
9861477 Backus et al. Jan 2018 B2
9867698 Kovalsky et al. Jan 2018 B2
9877830 Lim et al. Jan 2018 B2
9889029 Li et al. Feb 2018 B2
9895225 Rolando et al. Feb 2018 B2
9925045 Creaven et al. Mar 2018 B2
10179044 Ratz Jan 2019 B2
20010007956 Letac et al. Jul 2001 A1
20020016623 Kula et al. Feb 2002 A1
20020032481 Gabbay Mar 2002 A1
20020045929 Diaz Apr 2002 A1
20020052644 Shaolian et al. May 2002 A1
20030105517 White et al. Jun 2003 A1
20030120333 Ouriel et al. Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030176914 Rabkin et al. Sep 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030220683 Minasian et al. Nov 2003 A1
20040117009 Cali et al. Jun 2004 A1
20040133273 Cox Jul 2004 A1
20040186561 McGuckin et al. Sep 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215325 Penn et al. Oct 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20050033398 Seguin Feb 2005 A1
20050075727 Wheatley Apr 2005 A1
20050090887 Pryor Apr 2005 A1
20050096738 Cali et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050137682 Justino Jun 2005 A1
20050159811 Lane Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050216079 MacOviak Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20060020327 Lashinski et al. Jan 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060173537 Yang et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060212110 Osborne et al. Sep 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20060293745 Carpentier et al. Dec 2006 A1
20070050021 Johnson Mar 2007 A1
20070100432 Case et al. May 2007 A1
20070129794 Realyvasquez Jun 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070255394 Ryan Nov 2007 A1
20080021546 Patz et al. Jan 2008 A1
20080082164 Friedman Apr 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080097581 Shanley Apr 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080228254 Ryan Sep 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090138079 Tuval et al. May 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090188964 Orlov Jul 2009 A1
20090270972 Lane Oct 2009 A1
20090276027 Glynn Nov 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281618 Hill et al. Nov 2009 A1
20090287296 Manasse Nov 2009 A1
20090287299 Tabor Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20100114305 Kang et al. May 2010 A1
20100121423 Bernhard et al. May 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249894 Oba et al. Sep 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100256723 Murray Oct 2010 A1
20100305685 Millwee et al. Dec 2010 A1
20110029067 McGuckin, Jr. et al. Feb 2011 A1
20110208297 Tuval et al. Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110224785 Hacohen Sep 2011 A1
20110264196 Savage et al. Oct 2011 A1
20120022633 Olson et al. Jan 2012 A1
20120022639 Hacohen et al. Jan 2012 A1
20120059454 Millwee et al. Mar 2012 A1
20120078360 Ratiee Mar 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123529 Levi et al. May 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120271398 Essinger et al. Oct 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20120310328 Olson et al. Dec 2012 A1
20130006294 Kashkarov et al. Jan 2013 A1
20130035759 Gross et al. Feb 2013 A1
20130053950 Rowe et al. Feb 2013 A1
20130144378 Quadri et al. Jun 2013 A1
20130211508 Lane et al. Aug 2013 A1
20130253635 Straubinger et al. Sep 2013 A1
20130253642 Brecker Sep 2013 A1
20130274873 Delaloye et al. Oct 2013 A1
20130310928 Morriss Nov 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20130338766 Hastings et al. Dec 2013 A1
20130345786 Behan Dec 2013 A1
20140018912 Delaloye et al. Jan 2014 A1
20140025163 Padala et al. Jan 2014 A1
20140039611 Lane et al. Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140052242 Revuelta et al. Feb 2014 A1
20140100651 Kheradvar et al. Apr 2014 A1
20140100653 Savage et al. Apr 2014 A1
20140142694 Tabor et al. May 2014 A1
20140155997 Braido Jun 2014 A1
20140163668 Rafiee Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172083 Bruchman et al. Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140207231 Hacohen et al. Jul 2014 A1
20140214153 Ottma et al. Jul 2014 A1
20140214154 Nguyen et al. Jul 2014 A1
20140214155 Kelley Jul 2014 A1
20140214159 Vidlund Jul 2014 A1
20140214160 Naor Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222139 Nguyen et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140230515 Tuval et al. Aug 2014 A1
20140236288 Lambrecht et al. Aug 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140277390 Ratz Sep 2014 A1
20140277402 Essinger et al. Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140296973 Bergheim et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303719 Cox et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140330371 Gloss et al. Nov 2014 A1
20140330372 Weston et al. Nov 2014 A1
20140336754 Gurskis et al. Nov 2014 A1
20140343669 Lane et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140343671 Yohanan et al. Nov 2014 A1
20140350663 Braido et al. Nov 2014 A1
20140350666 Righini Nov 2014 A1
20140350668 Delaloye et al. Nov 2014 A1
20140358223 Rafiee et al. Dec 2014 A1
20140364939 Deshmukh et al. Dec 2014 A1
20140364943 Conklin Dec 2014 A1
20140371842 Marquez et al. Dec 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140371845 Tuval et al. Dec 2014 A1
20140371847 Madrid et al. Dec 2014 A1
20140371848 Murray, III et al. Dec 2014 A1
20140379067 Nguyen et al. Dec 2014 A1
20140379068 Thielen et al. Dec 2014 A1
20150005863 Para Jan 2015 A1
20150018938 Von Segesser et al. Jan 2015 A1
20150018944 O'Connell et al. Jan 2015 A1
20150039083 Rafiee Feb 2015 A1
20150045880 Hacohen Feb 2015 A1
20150142103 Vidlund May 2015 A1
20150148731 McNamara et al. May 2015 A1
20150157457 Hacohen Jun 2015 A1
20150157458 Thambar et al. Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150209141 Braido et al. Jul 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150297346 Duffy et al. Oct 2015 A1
20150327994 Morriss et al. Nov 2015 A1
20150328001 McLean et al. Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20160000591 Lei et al. Jan 2016 A1
20160030169 Shahriari Feb 2016 A1
20160030170 Alkhatib et al. Feb 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160038281 Delaloye et al. Feb 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160106537 Christianson et al. Apr 2016 A1
20160113765 Ganesan et al. Apr 2016 A1
20160113766 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160143732 Glimsdale May 2016 A1
20160158010 Lim et al. Jun 2016 A1
20160166383 Lim et al. Jun 2016 A1
20160184097 Lim et al. Jun 2016 A1
20160199206 Lim et al. Jul 2016 A1
20160213473 Hacohen et al. Jul 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160279386 Dale et al. Sep 2016 A1
20170128209 Morriss et al. May 2017 A1
20170216023 Lane et al. Aug 2017 A1
20170216575 Asleson et al. Aug 2017 A1
20170258614 Griffin Sep 2017 A1
20170325954 Perszyk Nov 2017 A1
20170348096 Anderson Dec 2017 A1
20170367823 Hariton et al. Dec 2017 A1
20180055636 Valencia et al. Mar 2018 A1
20180085218 Eidenschink Mar 2018 A1
20180110534 Gavala et al. Apr 2018 A1
Foreign Referenced Citations (101)
Number Date Country
2304325 Oct 2000 CA
2827556 Jul 2012 CA
102869319 Jan 2013 CN
102006052564 Dec 2007 DE
1171059 Jan 2002 EP
1369098 Dec 2003 EP
1472996 Nov 2004 EP
1259194 Feb 2005 EP
1734903 Dec 2006 EP
1255510 Apr 2007 EP
1827558 Sep 2007 EP
1239901 Oct 2007 EP
1935377 Mar 2010 EP
2237746 Oct 2010 EP
2238947 Oct 2010 EP
2285317 Feb 2011 EP
2308425 Apr 2011 EP
2398543 Dec 2011 EP
1281375 Feb 2012 EP
2496182 Sep 2012 EP
2566416 Mar 2013 EP
2319458 Apr 2013 EP
2124826 Jul 2014 EP
2750630 Jul 2014 EP
2777617 Sep 2014 EP
2815723 Dec 2014 EP
2815725 Dec 2014 EP
2898858 Jul 2015 EP
2967858 Jan 2016 EP
2168536 Apr 2016 EP
2262451 May 2017 EP
3184083 Jun 2017 EP
2446915 Jan 2018 EP
3057541 Jan 2018 EP
3037064 Mar 2018 EP
3046511 Mar 2018 EP
3142603 Mar 2018 EP
3294220 Mar 2018 EP
1264471 Feb 1972 GB
1315844 May 1973 GB
2398245 Aug 2004 GB
2002540889 Dec 2002 JP
9749355 Dec 1997 WO
0061034 Oct 2000 WO
03092554 Nov 2003 WO
2004030569 Apr 2004 WO
2005011534 Feb 2005 WO
2006070372 Jul 2006 WO
2006085225 Aug 2006 WO
2006089236 Aug 2006 WO
2007025028 Mar 2007 WO
2007058857 May 2007 WO
2007123658 Nov 2007 WO
2008013915 Jan 2008 WO
2008070797 Jun 2008 WO
2008103722 Aug 2008 WO
2008125153 Oct 2008 WO
2008150529 Dec 2008 WO
2009026563 Feb 2009 WO
2009045331 Apr 2009 WO
2009053497 Apr 2009 WO
2009091509 Jul 2009 WO
2009094500 Jul 2009 WO
2009134701 Nov 2009 WO
2010005524 Jan 2010 WO
2010008549 Jan 2010 WO
2010022138 Feb 2010 WO
2010040009 Apr 2010 WO
2010057262 May 2010 WO
2011025945 Mar 2011 WO
2011057087 May 2011 WO
2011111047 Sep 2011 WO
2011137531 Nov 2011 WO
2012095159 Jul 2012 WO
2012177942 Dec 2012 WO
2013028387 Feb 2013 WO
2013059747 Apr 2013 WO
2013059747 Apr 2013 WO
2013075215 May 2013 WO
2013120181 Aug 2013 WO
2013175468 Nov 2013 WO
2013192305 Dec 2013 WO
2014018432 Jan 2014 WO
2014022124 Feb 2014 WO
2014022124 Feb 2014 WO
2014099655 Jun 2014 WO
2014110019 Jul 2014 WO
2014110171 Jul 2014 WO
2014121042 Aug 2014 WO
2014139545 Sep 2014 WO
2014145338 Sep 2014 WO
2014149865 Sep 2014 WO
2014163706 Oct 2014 WO
2014164364 Oct 2014 WO
2014194178 Dec 2014 WO
2014204807 Dec 2014 WO
2014205064 Dec 2014 WO
2014210124 Dec 2014 WO
2015077274 May 2015 WO
2015148241 Oct 2015 WO
2016016899 Feb 2016 WO
Non-Patent Literature Citations (52)
Entry
Backer, Ole De, MD, et al., “Percutaneous Transcatheter Mitral Valve Replacement—An Overview of Devices in Preclinical and Early Clinical Evaluation,” Contemporary Reviews in Interventional Cardiology, Circ Cardiovasc Interv. 2014;7:400-409, Applicant believes this may have been available as early as June of 2014.
Banai, Shmeul et al., The Journal of the American College of Cardiology, “Transapical Mitral Implantation of the Tiara Bioprosthesis Pre-Clinical Results,” Feb. 2014, <http://interventions.onlinejacc.org/article.aspx? articleid=1831234>.
Bavaria, Joseph E. M.D. et al.: “Transcatheter Mitral Valve Implantation: The Future Gold Standard for MR?,” Applicant requests the Examiner to consider this reference to be prior art as of December of 2010.
Bavaria, Joseph E. MD: “CardiAQ Valve Technologies: Transcatheter Mitral Valve Implantation,” Sep. 21, 2009.
Berreklouw, Eric, PhD, et al., “Sutureless Mitral Valve Replacement With Bioprostheses and Nitinol Attachment Rings: Feasibility in Acute Pig Experiments,” The Journal of Thoracic and Cardiovascular Surgery, vol. 142, No. 2, Aug. 2011 in 7 pages, Applicant believes this may have been available online as early as Feb. 7, 2011.
BioSpace, “CardiAQ Valve Technologies (CVT) Reports Cardiovascular Medicine Milestone: First-In-Humannonsurgical Percutaneous Implantation of a Bioprosthetic Mitral Heart Valve,” Jun. 14, 2012, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports/263900.
BioSpace, “CardiAQ Valve Technologies (CVT) Reports First-In-Human Percutaneous Transfemoral, Transseptal Implantation With Its Second Generation Transcatheter Bioprosthetic Mitral Heart Valve,” Jun. 23, 2015, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports-first-in/382370.
Boudjemline, Younes, et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves,” JACC, vol. 46, No. 2, Jul. 19, 2005:360-5.
“CardiAQTM Valve Technologies reports Successful First-in-Human Trans-Apical implantation of its Second Generation Transcatheter Mitral Valve,” CardiAQ Valve Technologies Press Release, May 20, 2014.
CardiAQ Valve Technologies, “Innovations in Heart Valve Therapy,” In3 San Francisco, Jun. 18, 2008, PowerPoint presentation in 19 slides.
Chiam, Paul T.L., et al., “Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials,” JACC: Cardiovascular Interventions, The American College of Cardiology Foundation, vol. 1, No. 4, Aug. 2008:341-50.
“Company Overview,” at TVT on Jun. 25, 2009.
Condado, Jose Antonio, et al., “Percutaneous Treatment of Heart Valves,” Rev Esp Cardio. 2006;59(12):1225-31, Applicant believes this may have been available as early as December of 2006.
Engager System, Precise Valve Positioning, Transcatheter Aortic Valve Implantation System, Transcatheter Aortic Valve Replacement—TAVR I Medtronic Engager, http://www.medtronic-engager.com/home/transcatheter-aortic-valve-repl., 2014 Medtronic, Inc. in 2 pages. Applicant believes this may have been available online as early as Aug. 25, 2013.
Fanning, Jonathon P., et al., “Transcatheter Aortic Valve Implantation (TAVI): Valve Design and Evolution,” International Journal of Cardiology 168 (2013) 1822-1831, Applicant believes this may have been available as early as Oct. 3, 2013.
Fornell, Dave, “Transcatheter Mitral Valve replacement Devices in Development,” Diagnostic and Interventional Cardiology, Dec. 30, 2014, p. 3, <http://www.dicardiology.com/article/transcatheter-mitral-valve-replacement-devices-development>.
Fitzgerald, Peter J. M.D., “Tomorrow's Technology: Percutaneous Mitral Valve Replacement, Chordal Shortening, and Beyond,” Transcatheter Valve Therapies (TVT) Conference. Seattle, WA. Applicant believes this may have been available as early as Jun. 7, 2010.
Feldman, Ted, MD. “Prospects for Percutaneous Valve Therapies,” Circulation 2007;116:2866-2877. Applicant believes that this may be available as early as Dec. 11, 2007.
Grube, E. et al, “Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.” J Am Coll Cardiol. Jul. 3, 2007;50(1):69-76. Epub Jun. 6, 2007.
Horvath et al.: “Transapical Aortic Valve Replacement under Real-time Magnetic Resonance Imaging Guidance: Experimental Results with Balloon-Expandable and Self-Expanding Stents,” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038190/. Jun. 2011.
Kronemyer, Bob, “CardiAQ Valve Technologies: Percutaneous Mitral Valve Replacement,” Start Up—Windhover Review of Emerging Medical Ventures, vol. 14, Issue No. 6, Jun. 2009, pp. 48-49.
Lutter, Georg, et al., “Off-Pump Transapical Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 36 (2009) 124-128, Applicant believes this may have been available as early as Apr. 25, 2009.
Ostrovsky, Gene, “Transcatheter Mitral Valve Implantation Technology from CardiAQ,” medGadget, Jan. 15, 2010, available at: http://www.medgadget.com/2010/01/transcatheter_mitral_valve_implantation_technology_from_cardiaq.html.
Spillner, J. et al., “New Sutureless ‘Atrial-Mitral-Valve Prosthesis’ for Minimally Invasive Mitral Valve Therapy,” Textile Research Journal, 2010, in 7 pages, Applicant believes this may have been available as early as Aug. 9, 2010.
Karimi, Houshang, et al., “Percutaneous Valve Therapies,” SIS 2007 Yearbook, Chapter 11, pp. 1-11.
Leon, Martin B., et al., “Transcatheter Aortic Valve Replacement in Patients with Critical Aortic Stenosis: Rationale, Device Descriptions, Early Clinical Experiences, and Perspectives,” Semin. Thorac. Cardiovasc. Surg. 18:165-174, 2006 in 10 pages, Applicant believes this may have been available as early as the Summer of 2006.
Ma, Liang, et al., “Double-Crowned Valved Stents for Off-Pump Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 28 (2005) 194-199, Applicant believes this may have been available as early as August of 2005.
Mack, Michael M.D., “Advantages and Limitations of Surgical Mitral Valve Replacement; Lessons for the Transcatheter Approach,” Applicant believes this may have been available as early as Jun. 7, 2010. Applicant believes this may have been presented at the Texas Cardiovascular Innovative Ventures (TCIV) Conference in Dallas, TX on Dec. 8, 2010.
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: On-Going Experience in Swine Model,” Applicant believes this may have been presented on November of 2011 at TCT.
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: A Short-term Experience in Swine Model,” Applicant believes this may have been presented on May of 2011 at TVT.
Masson, Jean-Bernard, et al., “Percutaneous Treatment of Mitral Regurgitation,” Circulation: Cardiovascular Interventions, 2:140-146, Applicant believes this may have been available as early as Apr. 14, 2009.
Neovasc corporate presentation, Oct. 2009, available at http://www.neovasc.com/investors/documents/Neovasc-Corporate-Presentation-October-2009.pdf.
NJ350: Vote for Your Favorite New Jersey Innovations, Jun. 27, 2014, http://www.kilmerhouse.com/2014/06/nj350-vote-for-your-favorite-new-jersey-innovations/.
Piazza, Nicoló, MD, et al., “Anatomy of the Aortic Valvar Complex and Its Implications for Transcatheter Implantation of the Aortic Valve,” Contemporary Reviews in Interventional Cardiology, Circ. Cardiovasc. Intervent., 2008;1:74-81, Applicant believes this may have been available as early as August of 2008.
Pluth, James R., M.D., et al., “Aortic and Mitral Valve Replacement with Cloth-Covered Braunwald-Cutter Prosthesis, A Three-Year Follow-up,” The Annals of Thoracic Surgery, vol. 20, No. 3, Sep. 1975, pp. 239-248.
Preston-Maher, Georgia L., et al., “A Technical Review of Minimally Invasive Mitral Valve Replacements,” Cardiovascular Engineering and Technology, vol. 6, No. 2, Jun. 2015, pp. 174-184. Applicant believes this may have been available as early as Nov. 25, 2014.
Quadri, Arshad M.D., “Transcatheter Mitral Valve Implantation (TMVI) (An Acute In Vivo Study),” Applicant believes this may have been presented on Sep. 22, 2010 at TCT.
Ratz, J. Brent et al., “Any experiences making an expandable stent frame?” Arch-Pub.com, Architecture Forums: Modeling, Multiple forum postings from Feb. 3, 2009 to Feb. 4, 2009, http://www.arch-pub.com.
Ratz, J. Brent, “LSI EMT Spotlight,” May 15, 2009.
Ratz, J. Brent, “In3 Company Overview,” Jun. 24, 2009.
Ruiz, Carlos E., “Overview of Novel Transcatheter Valve Technologies,” Applicant believes this may have been presented on May 27, 2010 at EuroPCR.
Seidel, Wolfgang, et al., “A Mitral Valve Prosthesis and a Study of Thrombosis on Heart Valves in Dogs,” JSR—vol. II, No. 3—May, 1962, submitted for publication Oct. 9, 1961.
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” Applicant believes this may have been presented at TCT 2013.
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” Applicant believes this may have been presented at EuroPCR 2013.
Sondergaard, Lars, “CardiAQ TMVR FIH—Generation 2,” Applicants believe this may have been presented in 2014 at the TVT symposium.
Treede et al.: “Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30-day results of the multicentre CE-mark study.” http://ejcts.oxfordjournals.org/content/41/6/e131.long. Apr. 16, 2012.
Taramasso et al.: “New devices for TAVI: technologies and initial clinical experiences” http://www.nature.com/nrcardio/journal/v11/n3/full/nrcardio.2013.221.html?message-global=remove#access. Jan. 21, 2014.
“Update,” Applicant believes this may have been presented on Jun. 6, 2010 at TVT.
Van Mieghem, et al., “Anatomy of the Mitral Valvular Complez and Its Implications for Transcatheter Interventions for Mitral Regurgitation,” J. Am. Coll. Cardiol., 56:617-626 (Aug. 17, 2010).
Vu, Duc-Thang, et al., “Novel Sutureless Mitral Valve Implantation Method Involving A Bayonet Insertion and Release Mechanism: A Proof of Concept Study in Pigs,” The Journal of Thoracic and Cardiovascular Surgery, vol. 143, No. 4, 985-988, Apr. 2012, Applicant believes this may have been available online as early as Feb. 13, 2012.
Wayback Machine, Cleveland Clinic Lerner Research Institute, Transcatheter Mitral Stent/Valve Prosthetic, https://web.archive.org/web/20130831094624/http://mds.clevelandclinic.org/Portfolio.aspx?n=331, indicated as archived on Aug. 31, 2013.
Webb, John G., et al., “Transcatheter Aortic Valve Implantation: The Evolution of Prostheses, Delivery Systems and Approaches,” Archives of Cardiovascular Disease (2012) 105, 153-159. Applicant believes this may have been available as early as Mar. 16, 2012.
Related Publications (1)
Number Date Country
20190142585 A1 May 2019 US
Provisional Applications (1)
Number Date Country
62000309 May 2014 US
Continuations (2)
Number Date Country
Parent 15462438 Mar 2017 US
Child 16247403 US
Parent 14716507 May 2015 US
Child 15462438 US